



HHS Public Access

Author manuscript

Cell. Author manuscript; available in PMC 2023 September 29.

Published in final edited form as:

Cell. 2022 September 29; 185(20): 3652–3670. doi:10.1016/j.cell.2022.08.026.

Epstein-Barr Virus (EBV): Biology and Clinical Disease

Blossom Damania^{1,*}, Shannon C. Kenney², Nancy Raab-Traub¹

¹Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

²Department of Oncology, McArdle Laboratory for Cancer Research, and Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA

SUMMARY

Epstein-Barr virus (EBV) is a ubiquitous, oncogenic virus that is associated with a number of different human malignancies as well as autoimmune disorders. The expression of EBV viral proteins and non-coding RNAs contribute to EBV-mediated disease pathologies. The virus establishes life-long latency in the human host and is adept at evading host innate and adaptive immune responses. In this review, we discuss the lifecycle of EBV, the various functions of EBV encoded proteins and RNAs, the ability of the virus to activate and evade immune responses, as well as the neoplastic and autoimmune diseases that are associated with EBV infection in the human population.

INTRODUCTION

Epstein-Barr Virus (EBV) also known as human herpesvirus 4 (HHV-4) is a member of the gammaherpesvirus family. EBV belongs to the gamma 1 or lymphocryptovirus genus and was identified as the first human tumor virus. EBV was first discovered in 1964 in Burkitt lymphoma and was later found to also be associated with other types of lymphoma including Hodgkin lymphoma, non-Hodgkin lymphoma in posttransplant patients and HIV-infected individuals, T-cell lymphoma, and NK/T cell lymphoma (Gewurz, 2021) (Table 1). EBV is also associated with epithelial cancers including nasopharyngeal carcinoma and a subset of gastric cancers (Table 1). In addition to its association with different forms of human cancer, EBV is also linked with non-malignant disease including infectious mononucleosis, oral hairy leukoplakia, system lupus erythematosus and multiple sclerosis.

EBV infects over 95% of the world's population and is a highly successful pathogen. Primary infection is often asymptomatic and occurs at a young age in developing countries and at a later age in more industrialized countries (Gewurz, 2021). EBV is intermittently shed in saliva in healthy individuals. In the U.S., the seroprevalence of EBV antibody ranges

*Correspondence: damania@med.unc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

from 50% in children to 89% in teenagers (Lunn et al., 2017). When primary infection occurs after childhood, it can result in infectious mononucleosis (Vedham et al., 2015). EBV transmission primarily occurs through saliva. However, breast milk, bodily fluids, and transplantation of EBV-positive organs can also spread the virus from one host to another. There are two types of EBV isolates-type 1 and type 2, which have sequence polymorphisms in the EBNA2 and EBNA3 genes. Type 2 EBV has decreased lymphocyte transformation capacity (Tzellos et al., 2014).

Coinfections with both type 1 and type 2 isolates can occur. EBV establishes life-long persistence in the human host by infecting B cells and residing in memory B cells in healthy people where it is asymptomatic and does not cause disease. However, both intrinsic factors (e.g. genetic mutations and deficiencies) and extrinsic factors (e.g. immunosuppression, HIV infection, salted or preserved fish diet) can result in the development of EBV-associated cancers.

Similar to other herpesviruses, EBV has two distinct phases of its life-cycle- latency and lytic replication. During the latent phase, the virus is present in the nucleus as a circular episome tethered to the host genome chromatin utilizing a viral protein named EBNA-1. Under latent conditions, the virus expresses a small fraction of viral genes and non-coding RNAs and depending on the cell type infected, distinct latent gene expression programs have been observed. During latency, the virus is dependent on normal cellular division processes, including the host DNA replication machinery to passively replicate its viral genome and be transmitted to daughter cells.

Latency is a hallmark of EBV, and the virus establishes life-long latency in humans with only sporadic episodes of reactivation and lytic replication. Under certain conditions the virus is able to reactivate and enter the lytic cycle where all viral genes are expressed, and the virus can replicate its viral genome and produce infectious progeny viruses. Lytic replication typically results in cell death and release of infectious virus that can infect naïve cells in the same host or be transmitted to new hosts. However, abortive lytic expression can also occur where the virus expresses a sub-set of lytic genes but does not enter full blown lytic replication (Gewurz, 2021).

VIRAL ENTRY

Saliva is the primary route of EBV transmission. EBV infects epithelial cells in the oropharynx where it can replicate and subsequently infect B cells that traffic to the oral cavity (Figure 1). Alternatively, the virus in saliva may also directly infect B cells in the oral cavity after epithelial transcytosis.

Depending on the cell type, different EBV glycoproteins participate in epithelial versus B cell infection. During B cell infection, EBV gp350/220 binds the complement receptor CD21 present on B cells or can also utilize another complement receptor, CD35 (Fingerroth et al., 1984; Ogembo et al., 2013). CD21 is also expressed on T cells and may be utilized to infect T cells as well (Smith et al., 2020). Although EBV infection of B cells involves gp350/220 attachment to CD21, epithelial cells lack CD21 and hence, gH is used for

attachment. Following attachment, three EBV glycoproteins, gH, gL and gp42 participate in viral entry. In B cells, entry involves the binding of gp42 to HLA class II molecules, which functions as a co-receptor, while in epithelial cells lacking HLA class II, entry does not require gp42 and is instead mediated only by the gH-gL complex (Borza and Hutt-Fletcher, 2002). During EBV replication in epithelial cells, gp42 binds to the gH-gL complex. However, when the virus replicates in B cells, gp42 is instead sequestered with HLA class II protein and hence the virus emanating from B cells lacks gp42 in the gH-gL complex, which makes this virus more efficacious in infecting epithelial cells rather than fellow B cells. In summary, virus that arises from replication in epithelial cells can efficiently infect B lymphocytes, while virus that originates from replication in B cells has a superior capacity to infect epithelial cells (Borza and Hutt-Fletcher, 2002). Thus, the virus appears to switch effortlessly between infection of these two different cell types.

Following entry, EBV virions are endocytosed into B cells (Tanner et al., 1987) and the membrane of the virus fuses with the endosomal membrane (Chesnokova et al., 2014). This event is mediated by EBV gH/gL and gB (Chesnokova et al., 2014). On the other hand, EBV was first thought to enter epithelial cells through direct fusion of the viral membrane with the cell membrane (Miller and Hutt-Fletcher, 1992). More recently however, it was reported that EBV can also enter epithelial cells via lipid raft-dependent endocytosis and micropinocytosis mediated by neuropilin 1 (NRP1), which interacts with EBV gB (Wang et al., 2015). EBV gp350 or BMRF2 can mediate attachment to the epithelial cell while gB and gH/gL appear to be involved in epithelial entry and fusion (Chen and Longnecker, 2019). Host proteins involved in epithelial cell infection include integrins, NRP1, and ephrin receptor A2 (EphA2) (Chen and Longnecker, 2019). In fact, EphA2 is thought to play a critical role in epithelial cell infection (Chen et al., 2018; Zhang et al., 2018)

EBV LATENCY

Early Events after Infection

As described above, EBV efficiently infects B lymphocytes and establishes latency where several viral proteins are expressed through a carefully regulated and complex mechanism (Gewurz, 2021). The viral genome is separate from host DNA and is retained as an extrachromosomal episome wrapped in nucleosomes, a characteristic of herpesvirus latency (Gewurz, 2021). BNRF1, a EBV tegument protein, promotes establishment of latency through inhibition of the ATRX/DAXX complex that would otherwise deposit repressive histone complexes on the incoming EBV genome (Tsai et al., 2011).

Following infection of B-lymphocytes, the EBV genome circularizes through the terminal repeats (TR). The TR number can be used to distinguish individual cellular infections and used as surrogate marker for cell clonality (Raab-Traub and Flynn, 1986). During cell division, the viral genome is subsequently replicated by the host DNA polymerase with replication initiated at the origin of plasmid replication, OriP, and partitioned to the daughter cells (Gewurz, 2021). During latency and transformation, the virus does not undergo lytic replication to produce progeny virions. The relative abundance of cellular transcription factors dictates in part the activity of viral promoters. In B-lymphocytes, specific factors, including YY1 and Pax5, activate the first viral promoter, Wp, to initiate a complexly

spliced mRNA transcribed through the W repeat sequence, IR1 (Gewurz, 2021). Through interaction with a host cell DNA binding protein, RBP-Jk, EBNA2 then activates the EBV C promoter (Cp). Transcription at Cp produces an approximately 125 kilobase EBV transcript, which expresses six EBNAs through alternatively splicing.

There are several types of EBV latency. Latency 0 displays expression of EBERs and BARTs and generally occurs in quiescent memory B cells. Latency I is the next most restricted pattern with expression of EBNA1, EBERs, and BARTs. Latency II displays expression of EBNA1, LMP1, LMP2, the EBERs, and high levels of BART expression. The most complex and best characterized is termed Latency III. Latency III displays expression of three integral latent membrane proteins (LMP1, 2A, 2B), six nuclear antigens (EBNA1, 2, 3A, 3B, 3C, and EBNA-LP), and multiple noncoding RNAs, the EBERs, BHRF1 miRNAs, and BARTs. It is important to note that there are also multiple subtypes with variations of a latency pattern expression where type I may sometimes include expression of LMP1 or BHRF1 and type II in some NPC may lack LMP1 expression. There are also variations in EBNA2 or 3 expression (Table 1).

Viral Gene Products Expressed during Latency

EBV Nuclear Antigens (EBNAs)—EBNA1 is needed for viral genome maintenance during latency. EBNA1 directly binds to OriP, to enable replication of the EBV genome by the host machinery in S-phase. The newly replicated viral genomes are tethered to the host genome and equally partitioned to daughter cells. OriP contains a family of repeats (FR), a dyad symmetry (DS) element, and two cis-acting elements that are critical for the retention of EBV episomes. FR contains multiple 18 bp copies of an EBNA1 recognition sequence and functions as an enhancer (with EBNA1) that is important for activation of Cp and expression of all of the EBNAs (Gewurz, 2021). EBNA1 also binds to and regulates certain cellular genes, and links the EBNA1/FR-bound episomes to condensed mitotic chromosomes (Gewurz, 2021). The actual origin of DNA synthesis resides within the DS element. DS contains 4 EBNA1 recognition sites and a 65 bp region of dyad symmetry and is essential for EBNA1 dependent plasmid replication. Recently, EBNA1 inhibitors have been shown to prevent EBV latency and tumor proliferation (Messick et al., 2019) in pre-clinical models.

EBNA2 was the first viral protein shown to be essential for B-lymphocyte growth transformation. EBNA2 is the major viral regulator of latent viral promoters and utilizes the DNA binding protein RBP-Jk to activate transcription. Binding of EBNA2 changes the activity of RBP-Jk from a repressor to an activator suggesting that EBNA2 mimics Notch-like signaling. Expression profiling has identified many genes that are regulated by EBNA2 and Chip-Seq has determined that thousands of sites are occupied by EBNA2 and RBP-Jk. Intriguingly, EBNA2 has been shown to bind to hundreds of super-enhancer sites which then loop between distal sites and regulate concomitant expression of multiple cellular genes (Gewurz, 2021).

EBNA-LP. LP is produced by an RNA that contains differing numbers of copies of the W repeat ORFs and two exons from BamHI Y. LP is produced with EBNA2 to which it binds and functions as a coactivator (Gewurz et al., 2012). LP localizes with promyelocytic

leukemia (PML) nuclear bodies and is thought to modulate chromatin structure through effects on histone acetylation (Ling et al., 2005). Recent analyses suggest that EBNA2 may loop super-enhancers to promoters bound by LP. Interestingly, LP is essential for transforming naïve cord blood B cells (Mannick et al., 1991).

EBNA3 A, B, and C The EBNA3 proteins are produced by alternate splicing of the long Cp initiated mRNA. Importantly, it was determined that they each bind RBP-J κ (Robertson et al., 1996). The proteins share several domains and each EBNA3 has transcription repression activity. Like most of the EBV latency proteins, EBNA3A, 3B and 3C do not have homology to host proteins. EBNA3s compete with EBNA2 for binding to RBP-J κ and can repress EBNA2 transactivation. They also can repress transcription through association with and assembly of host repressor complexes. EBNA3A also inhibits apoptosis through effects on expression of MCL-1 and BFL-1 (Price et al., 2017). EBNA3A/3C promote proliferation and inhibit senescence by blocking expression of p16 and p14 (ARF), and EBNA3C is required for transformation of B lymphocytes unless the p16 gene is deleted (Styles et al., 2017). EBNA3A and 3C also inhibit plasma cell differentiation by decreasing PRDM1 expression (Pei et al., 2017)

Latent Membrane Proteins

Latent membrane protein 1 (LMP1): LMP1 is required for *in vitro* B cell transformation and was the first viral oncoprotein identified in cultured cell lines. LMP1 gene expression has been detected in many EBV associated cancers including PTL, HD and NPC. LMP1 is enriched in lipid rafts in the plasma membrane of lymphocytes and within endosomes. Characterization of proteins that bind to LMP1 identified molecules subsequently shown to interact with tumor necrosis factor receptors (TRAFs) and suggested that aggregation from its multiple membrane spanning domains allows LMP1 to function as a constitutively active member of the tumor necrosis factor receptor family (Miller et al., 1998) (Figure 2A). The TRAFs bind to two regions within the long carboxy terminal domain of LMP1, CTAR1 and CTAR2. These domains bind distinct TRAFs and have unique properties. The two domains and the specific TRAFs suggest that LMP1 most closely mimics CD40 (Hatzivassiliou et al., 1998). C-terminal activating region 2 (CTAR2) activates the canonical NF- κ B pathway and formation of p50/p65 complexes and activation of JNK through interactions with adapter proteins and TRAF6. C-terminal activating region 1 (CTAR1) activates canonical and noncanonical NF- κ B pathways resulting in distinct NF- κ B dimers e.g. p50/50, p52/p65, and p52/p50 (Gewurz et al., 2012; Luftig et al., 2003). CTAR1 also activates PI3K and upregulates epidermal growth factor receptor (EGFR) expression (Mainou et al., 2007). Induced p50-Bcl-3 complexes can bind to NF- κ B consensus motifs on the EGFR promoter (Edwards et al., 2015). A third domain that contains the TRAF motif (CTAR3) interacts with the SUMO conjugating enzyme, UBC9 (Bentz et al., 2011)

Exosomes are small vesicles containing proteins and RNA that are released from cells (Raab-Traub and Dittmer, 2017). EBV-infected cells secrete LMP1-containing exosomes that inhibit peripheral blood mononuclear cell proliferation. NPC cells secrete exosomes that contain LMP1 and galectin 9, a protein that induces T cell death (Klibi et al., 2009). LMP1 upregulates secretion of exosomes containing fibroblast growth factor and EGFR.

The purified exosomes containing LMP1 and EGFR are taken up by epithelial, fibroblast, and endothelial cells leading to the activation of PI3K/Akt and ERK pathways (Meckes et al., 2010). Thus, exosomes secreted from EBV-infected cells can alter proliferation of neighboring and distant cells (Raab-Traub and Dittmer, 2017).

Latent Membrane Protein 2 (LMP2A): LMP2A is also an important signal transducer in EBV infected cells that oligomerizes in lipid rafts and in B-cells can mimic a constitutively activated B cell receptor (BCR) and also transduce downstream signaling including the NF- κ B pathway (Longnecker and Miller, 1996). It contains several SH2 domains that can bind Src family kinases such as Lyn in B cells, an immunoreceptor tyrosine-based activation motif (ITAM) which interacts with Syk kinase, and PY motifs that interact with the Nedd4 family of ubiquitin ligases (Figure 2B). ITAM activation results in the phosphorylation and activation of Akt, inhibition of GSK3b and subsequent activation of β -catenin signaling. This prevents differentiation of epithelial cells. LMP2A can also transform epithelial cells, inhibit anoikis, and promote migration and anchorage independence through the function of its ITAM and the PY domains (Fotheringham and Raab-Traub, 2015). LMP2A expression in B cells in transgenic mice allows survival of B cells in the absence of a functional BCR, and affects Btk, Erk, and Notch signaling (Anderson and Longnecker, 2009). In vivo, its consistent expression at high levels in Reed-Sternberg cells in HD and EBV related carcinomas confirms its important role in latency and pathogenesis.

Viral non-coding RNAs

EBV Encoded RNAs (EBERs): The small nuclear EBER RNAs, EBER1 and EBER2, are the most abundant RNAs in EBV-infected cells (Gewurz et al., 2012), with approximately 10^5 copies per cell. The EBERs are expressed during all the different latency states and are used as a marker for latently infected cells. They are transcribed by RNA polymerase III and also tightly bind the La protein suggesting that they may affect pol III transcripts. They are primarily nuclear although interactions with important cytosolic proteins have been described. Although not essential for B-cell transformation, the EBERs likely contribute to maintenance of latency and transformation (Swaminathan et al., 1991). EBER2 has been shown to increase expression of the UCHL1 deubiquitinase, which likely contributes to transformation (Bentz et al., 2014; Li et al., 2021).

BamHI A Encoded Transcripts (BARTs): EBV expression in NPC includes high level transcription of a family of rightward transcripts from the *Bam* HIA region that are expressed at lower levels in lymphoid cell lines (Gilligan et al., 1991). The *Bam* HIA transcripts (also called BARTs or CSTs) are differentially spliced and generate RNAs that are 3' co-terminal. The C15 NPC tumor transcripts display alternate splicing of at least 7 exons that form several potential ORFs; however, none of these proteins have been confirmed.

Forty-four miRNAs arise from the introns of the BART transcripts (the BART miRNAs) (Pfeffer et al., 2004) and three miRNAs arise from around the BHRF1 ORF (Cai et al., 2006). Some of the miRNAs may regulate viral mRNAs, however, most regulate host transcripts. Many potential targets have been identified with clear effects on apoptosis,

tumor suppressors, and immune regulation. The spliced BART RNAs have also been shown to function as long non-coding RNAs (lncRNA) with the potential for sponging and inactivating tumor suppressor miRNAs (Marquitz et al., 2015). Interestingly, EBV miRNAs can be secreted in exosomes and affect neighboring cells (Pegtel et al., 2010). Exosomes can be secreted during all forms of latency and potentially transfer viral oncoproteins, ncRNAs, and key signaling molecules (Raab-Traub and Dittmer, 2017). This may modulate the tumor microenvironment.

Multiple other nc RNAs have been identified in EBV including a small nucleolar RNA encoded by the BART region and several potential circular RNAs from multiple regions of the genome (Moss et al., 2014; Ungerleider et al., 2019).

EBV REACTIVATION AND REPLICATION

Clinical importance of lytic EBV infection

The lytic form of EBV infection is required for production of infectious virions and is thus essential for the transmission of the virus from cell to cell and host to host. Lytic EBV replication can be inhibited by FDA-approved drugs, including ganciclovir, acyclovir and foscarnet (Pagano et al., 2018). Chronic acyclovir therapy in healthy volunteers decreases the number of EBV-infected B cells (Hoshino et al., 2009), suggesting that EBV reactivation and replication may function to replenish the latently infected cell reservoir in the infected host. In oral hairy leukoplakia lytic EBV infection of differentiated squamous epithelium produces white tongue lesions in immunocompromised hosts (Gewurz, 2021). Although a lytic-defective EBV mutant can transform B cells *in vitro* (Feederle et al., 2000), and EBV-positive malignancies are composed almost entirely of latently infected cells, there is growing evidence that lytic infection contributes to the early development of EBV-induced tumors. A lytic-defective EBV mutant missing the BZLF1 immediate-early gene is partially defective in inducing lymphomas in a humanized mouse model (Ma et al., 2011), and lymphoblastoid B cell lines (LCLs) created with this mutant form tumors less efficiently than LCLs with wild-type EBV in SCID mice (Hong et al., 2005a). In addition, lytically-infected cells in tumors (although relatively rare) produce growth factors such as IL6 (Jones et al., 2007), angiogenesis factors such as VEGF (Hong et al., 2005b), and immunosuppressive factors such as IL10 (Mahot et al., 2003) that may promote proliferation and survival of latently infected tumor cells. Furthermore, abortive lytic infection may contribute to cellular gene mutations/alterations that drive EBV-positive tumors. In addition, EBV genomes containing variants of the viral BZLF1 promoter and EBER2 small nuclear RNA that cause increased lytic EBV infection (Bristol et al., 2018; Farrell and White, 2021) are highly over-represented in viruses isolated from EBV-positive nasopharyngeal carcinomas in China versus virus isolated from healthy controls in the same region (Li et al., 2019).

Overview of lytic EBV replication

Lytic EBV genes are classified as immediate-early (IE), early or late lytic genes, with the names reflecting the temporal order in which they are expressed (Gewurz et al., 2012). EBV infection of normal differentiated oropharyngeal epithelial cells results in lytic infection

without concomitant establishment of viral latency (Temple et al., 2014). On the other hand, EBV infection of B cells initially results in viral latency, although the virus can subsequently switch to the lytic form of infection (“lytically reactivate”) when cells undergo B-cell receptor (BCR) activation or differentiate into plasma cells (Kenney and Mertz, 2014). Lytic reactivation is mediated by expression of the two viral Immediate-early (IE) lytic proteins, BZLF1 (aka Z, ZTA, ZEBRA) and BRLF1 (aka R, RTA)(Countryman and Miller, 1985; Deng et al., 2003; Flemington et al., 1992; Rooney et al., 1989; Zalani et al., 1996).

Z and R encode viral transcription factors that together activate expression of each of the early lytic EBV proteins required for the lytic form of EBV viral DNA replication, including the virally-encoded DNA polymerase (BALF5) (Fixman et al., 1992; Kenney and Mertz, 2014), using the lytic origin of replication, OriLyt (Hammerschmidt and Sugden, 1988). Early lytic gene promoters contain cis-acting motifs that bind to Z and/or R (“ZREs” and “RREs,” respectively), and are transcriptionally activated when bound by the Z and/or R proteins (Kenney and Mertz, 2014). Transcription of late lytic EBV genes, which encode proteins required for virion assembly, occurs after viral genome replication and requires both a cis-acting viral replication origin and the virally-encoded preinitiation complex (vPIC) that recruits RNA polymerase II (Aubry et al., 2014; Chiu et al., 2013; Djavadian et al., 2016). The EBV early lytic SM protein is also required for transcription of a subset of late lytic genes, and this effect may be mediated through recruitment of the cellular transcription factor XPB to late promoters (Verma et al., 2020).

Lytic EBV DNA replication results in major reorganization of the host cell nucleus, with the viral replication compartments increasingly taking up most of the nuclear space (Chiu et al., 2013). Newly replicated viral genomes, which are unmethylated and have no chromatin, are linearized via the viral terminase complex, and then packaged into a pre-formed capsid particle (Gewurz, 2021). The nucleocapsid complex then exits the nucleus (in the process acquiring, and then losing an envelope), and is deposited into the cytoplasm, where it becomes coated with viral proteins that form the “tegument” component of the virion particle (the region between the nucleocapsid and the virion envelope)(Gewurz, 2021). The particles then acquire a final envelope by budding into cis-Golgi and trans-Golgi networks, and vesicles containing mature virions are fused to the plasma membrane and are released by exocytosis (Gewurz, 2021).

Regulation of lytic reactivation—The activity of the viral promoters driving Z and R expression (Z_p and R_p, respectively) is primarily regulated by cellular transcription factors. Biologically important inducers of lytic EBV reactivation in B cells include B-cell receptor activation and plasma cell differentiation (Kenney and Mertz, 2014; Laichalk and Thorley-Lawson, 2005). A variety of other stimuli, including hypoxia (via HIF-1 alpha), Hippo pathway signaling (via YAP/TAZ), inflammasome induction, and DNA damage can also induce lytic EBV reactivation (Burton et al., 2020; Kraus et al., 2017; Laichalk and Thorley-Lawson, 2005; Van Sciver et al., 2021b). In contrast, viral latency can be promoted by other cellular transcription factors including ZEB1/2, c-myc, KAP1, and IRF4 (Bristol et al., 2022; Guo et al., 2020a; Laichalk and Thorley-Lawson, 2005; Li et al., 2017). In differentiated oropharyngeal epithelial cells, EBV enters the lytic form of infection because the KLF4 and BLIMP1 cellular transcription factors collaboratively activate both

Zp and Rp (Nawandar et al., 2015; Sixbey et al., 1984). In contrast, EBV enters latency in undifferentiated epithelial cells due to absence of KLF4/BLIMP1 expression and the presence of delta Np63, which inhibits Zp activity (Van Sciver et al., 2021a).

CpG DNA methylation and 5-hydroxymethylation differentially regulate the Z and R IE proteins

Increasing evidence suggests that CpG methylation status of the viral genome determines whether Z versus R initially activates early lytic gene transcription during viral reactivation. The Z protein, a homolog of Jun and Fos, preferentially binds to and transcriptionally activates CpG methylated ZREs in early lytic viral promoters (Bhende et al., 2004; Kalla et al., 2010). In contrast, although R can bind to methylated or unmethylated RREs in early lytic promoters, it preferentially activates promoters that are unmethylated (Wille et al., 2013). In contrast to CpG methylation, 5-hydroxymethylation of ZREs by cellular TET proteins inhibits Z binding and activation (Wille et al., 2015). EBV promotes DNA methylation of most lytic EBV genes in B cells through LMP1- and LMP2A-induced DNMT3A and DNMT1 expression (Guo et al., 2020b). However, Zp remain unmethylated, ensuring that Zp can be activated by specific cellular transcription factors associated with lytic reactivation. In EBV-infected telomerase-immortalized normal oral keratinocytes (NOKs), the EBV genome becomes much less methylated and only R expression, and not Z expression, induces lytic reactivation (Wille et al., 2015). R binding to RREs is not affected by 5'hydroxymethylation, and TET2 enhances R-mediated (but inhibits Z-mediated) lytic EBV reactivation in latently infected cells. Although these results suggest that transcription factors that activate Rp (rather than Zp) initiate lytic reactivation in normal keratinocytes, both Z and R are required for completion of lytic viral DNA replication and production of infectious virus regardless of cell type (Wille et al., 2013).

IMMUNE RESPONSES TO EBV

Innate immune responses

The host uses two levels of defense to counter infections with pathogens: the innate immune system (initial recognition of the infecting microbe) and the adaptive immune system (systemic recognition and long-term immune memory of the microbe). The innate immune response activates the adaptive response, leading to pathogen clearance. Innate immunity is the first line of defense against EBV. Innate immune sensors also called pathogen recognition receptors (PRRs) recognize pathogen-associated molecular patterns (PAMPs) including DNA, RNA, and lipids present on viruses like EBV. PRRs include (TLRs), RIG-I like receptors (RLRs) and nucleotide-binding oligomerization domain, leucine rich repeat receptors (NLRs) (Kawai and Akira, 2008) and DNA sensors including cGAS and STING. cGAS signals through STING and is activated by viral DNA (Ma and Damania, 2016).

The PRRs important for EBV detection include Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and intracellular DNA sensors such as cGAS-STING and Absent in Melanoma-2 (AIM2)-like receptors (ALRs), including AIM2 and IFI16. Several TLRs have been shown to recognize EBV. TLR2 was shown to be activated by EBV and infection

of primary human monocytes with EBV resulted in increased MCP-1 expression that was dependent on TLR2 expression (Gaudreault et al., 2007).

RIG-I has been described to sense EBV-encoded small RNAs (EBERS) through an RNA polymerase III-dependent process (Ablasser et al., 2009; Chiu et al., 2009; Duan et al., 2015; Samanta et al., 2006). Consistent with this observation, gastric cancer cells depleted for RIG-I have reduced inflammatory cytokine production during EBV viral reactivation (Chiang et al., 2018). Furthermore, the ALR, IFI16, can detect the EBV viral genome and is co-localized on the EBV genome in latently infected B cells. Depletion of IFI16 allowed for upregulation of EBV gene expression and viral replication in B cells (Pisano et al., 2017).

Innate immune cells including natural killer (NK) cells and invariant natural-killer T (iNKT) cells and gamma-delta T cells also recognize EBV (Chung et al., 2013a; Djaoud et al., 2017; Yuling et al., 2009). EBV infection results in NK cell expansion (Balfour et al., 2013b) and these NK cells can recognize lytically infected cells (Chijioke et al., 2016). Moreover, iNKT cells are thought to recognize newly EBV-infected B cells. Finally, pDCs can produce interferon in response to EBV infection.

Adaptive immune responses

Adaptive immune responses recognize viral antigens and generate virus-specific immune responses that help to eliminate the virus from the infected host. Adaptive immunity involves the formation of immunologic memory so that future infection with the same virus can be curbed. Both B and T cells are part of the adaptive immune response to EBV.

EBV infection induces B cell activation resulting in increased production of IgM, IgG, and IgA. During the course of infectious mononucleosis (IM), antibodies against both latent and lytic viral antigens are detected. Neutralizing antibodies against gp350, gp42, and gH/gL can be found at varying times post-infection (Bu et al., 2019).

CD8⁺ T cells are important during both acute and persistent EBV infection. CD8⁺ T cells recognize EBV-infected cells because viral peptides are presented by MHC I molecules on the surface of the infected cells (Pudney et al., 2005). It has been reported that almost half of the CD8⁺ T cell population in newly infected people can be directed towards anti-EBV responses (Taylor et al., 2015).

IMMUNE EVASION BY EBV

Evasion of innate immunity

EBV has been reported to downregulate activation of several PRRs (Table 2). For example, EBV BPLF1 is a viral deubiquitinase that targets TRIF and MyD88 adaptor proteins as well as TRAF6 to downregulate both TRIF- and MyD88-dependent TLR activation and NF- κ B activation (Saito et al., 2013; van Gent et al., 2014). Thus, BPLF1 reduces proinflammatory cytokine responses to EBV. During EBV lytic infection, the expression of TLR9 was found to be significantly decreased at both the RNA and protein levels through the function of EBV BGLF5 which degrades the TLR9 RNA transcript (van Gent et al., 2011). Moreover, EBV LMP-1 was also found to reduce TLR9 transcription through repression of the TLR9

promoter (Fathallah et al., 2010). Interestingly, EBV appears to utilize TLR7 for replication. Some EBV EBER2 variants have been demonstrated to induce lytic EBV reactivation through the TLR7 signaling pathway, which is also important for reactivation of the related gammaherpesvirus, Kaposi sarcoma-associated herpesvirus (KSHV) (Gregory et al., 2009; Li et al., 2019).

EBV has also been shown to modulate RLR-mediated signaling through the mitochondrial adaptor protein, MAVS. EBV BHRF1 protein can promote mitochondrial fission leading to degradation of mitochondria and the MAVS protein, thereby reducing interferon signaling (Vilmen et al., 2020). Another viral protein, BPLF1, prevents TRIM25 from interacting with RIG-I through modulation of TRIM25 ubiquitination, thereby inhibiting the activation of RIG-I and preventing IFN induction (Gupta et al., 2019). In addition to viral proteins, EBV viral miRNAs also target RLRs. EBV miR-BART6-3p was shown to downregulate both RIG-I and interferon (Lu et al., 2017). EBV miR-BART15 can also target the NLRP3 inflammasome. (Haneklaus et al., 2012).

EBV also targets DNA sensing pathways. EBV infection activates the Tripartite motif-containing protein 29 (TRIM29), a protein that ubiquitinates and degrades the DNA sensor, STING, thereby resulting in decreased interferon responses in EBV-infected cells (Xing et al., 2017). It is postulated that APOBEC3B may convert cytosines to uracils in exposed single-stranded DNA replication intermediates of EBV, thereby inducing genomic mutations (Cheng et al., 2019). EBV BORF2 was demonstrated to inhibit the host DNA cytosine deaminase APOBEC3B (Cheng et al., 2019).

In addition to targeting specific PRR pathways as described above, EBV also targets multiple downstream components of the interferon signaling pathways including the interferon regulatory factors (IRFs), JAK/STAT signaling pathway, interferon-inducible genes (ISGs), as well as promoters of IFN alpha and beta. For example, both EBV LMP2A and LMP2B target interferon receptors for degradation (Shah et al., 2009), while BGLF2 interacts with Tyk2 to block interferon induction (Liu et al., 2020). Various mechanisms by which EBV modulates these central components of interferon signaling are reviewed in (Lange et al., 2022).

Evasion of adaptive immunity

EBV is also a master at evading adaptive immune responses. EBV BDLF3 inhibits MHC class I and II presentation by ubiquitination induced internalization (Quinn et al., 2016), while EBV BILF1 promotes the degradation of HLA-A and HLA-B (Griffin et al., 2013) (Table 2). Additionally, EBV BZLF2/gp42 functions to prevent MHC class II antigen presentation to T cells (Spriggs et al., 1996). Moreover, EBV BNLF2A inhibits the transporter associated with antigen processing (TAP) hindering peptide translocation from the cytoplasm to the endoplasmic reticulum (Jochum et al., 2012). Finally, EBV BPLF1 inhibits the proteasomal degradation of cytosolic proteins through its deubiquinating activity (Ernst et al., 2011). The EBV EBNA1 Gly-Ala repeats hinder protein synthesis of EBNA1 thereby preventing EBNA1 peptides from being presented to T cells (Yin et al., 2003). In a similar vein, LMP1 self-aggregation may prevent proteasome degradation and presentation to T cells (Smith et al., 2009), while EBV BCRF1 protein protects infected B cells from

NK-cell mediated killing (Jochum et al., 2012). EBNA1 downregulates the expression of the NKG2D ligands, ULBP1 and ULBP5, and c-Myc in order to prevent NK cells from killing EBV-infected B cells (Westhoff Smith et al., 2021). EBV-encoded microRNAs also inhibit CD8 T cell recognition of EBV-infected B cells by down-regulating expression of the peptide transporter subunit TAP2 and the cytokine IL-12 (Albanese et al., 2016).

EBV ONCOGENESIS

EBV associated cancers can be stratified based on their latent gene expression programs (Table 1). Latency I was first identified in Burkitt lymphoma and subsequently found to also be present in gastric carcinoma. A second sub-set of EBV-positive cancers have moderate EBV viral gene expression and express the type II latency program. Examples of these EBV-positive malignancies include NPC and HD. A third sub-set of EBV-positive cancers occur in immunocompromised or immunosuppressed individuals. Examples include HIV-associated lymphomas, post-transplant lymphoproliferative disease (PTLD) and lymphomas that arise in individuals with genetic immunodeficiencies. These cancers display type III latency (Wen et al., 2021).

In all EBV-associated cancers, EBV is present in every tumor cell, the viral genome is typically clonal or oligoclonal, and at least one or more EBV latent viral gene(s) is expressed in the neoplastic cell. EBV-associated tumors express multiple latent genes and latent gene expression is thought to drive oncogenesis of EBV-positive malignancies. However, as described above there, are multiple mechanisms through which lytic viral genes also contribute to tumorigenesis.

EBV-ASSOCIATED DISEASES

Infectious Mononucleosis

Infectious mononucleosis (IM) occurs in a subset of newly EBV-infected individuals, particularly in adolescents and young adults (Balfour et al., 2013a). The major symptoms of IM are fever, fatigue, sore throat, and lymphadenopathy, with patients commonly having a high number of atypical lymphocytes. By six weeks post-infection, up to 50% of the memory B cells are infected with EBV (Hochberg et al., 2004), although the great majority of atypical lymphocytes are activated CD8 T lymphocytes directed against latent and lytic viral antigens, particularly the viral IE proteins and EBNA3 proteins (Rickinson et al., 2014). The “mono spot” test, used to diagnose acute EBV infection, is positive in up to 90% of adolescent and young adult IM patients (Gewurz, 2021). Specific serologic tests for EBV antigens (particularly anti-VCA IgM antibody) can also be used to diagnose acute EBV infection. Although patients with IM are often ill for several weeks, they almost always recover unless they have genetic defects that impair their immune response to EBV.

EBV initially infects oropharyngeal B cells where it enters different forms of viral latency, including the growth promoting form (“type III”) that causes B cells to rapidly proliferate. The development of an effective CD8 T cell response eventually eliminates EBV-infected B cells with type III latency (Rickinson et al., 2014). Not surprisingly, anti-viral agents such

as acyclovir that inhibit lytic, but not latent, EBV infection do not shorten the course or improve the symptoms of IM (Pagano et al., 2018).

The clinical symptoms of IM are likely mediated by an excessively strong cytotoxic T cell response to EBV-infected B cells, associated with increased levels of pro-inflammatory cytokines and chemokines. Proposed explanations for the milder illness in newly EBV-infected children versus older individuals include (i) an increased ability of NK T cells in children to recognize and kill EBV infected B cells and (ii) a higher inoculum of EBV in infected adolescents/young adults associated with “deep kissing” behavior (Balfour et al., 2013a). In addition, genetic risk factors, including HLA type, clearly contribute to the risk for developing IM (Rostgaard et al., 2014).

EBV-induced Lymphoproliferative disease

EBV-induced lymphoproliferative disease (LPD) occurs when EBV-infected B cells contain the fully transforming form of latent EBV infection (“Type III” latency), in which all 9 latent EBV proteins are expressed. Type III latency is sufficient to transform B cells *in vitro* but is also highly immunogenic, and thus LPD only occurs in highly immunocompromised patients, such as transplant patients (where it is referred to as post-transplant lymphoproliferative disease) or patients with other disorders, including AIDS and inherited genetic mutations, affecting T cell or NK cell functions. Since EBV-encoded oncoproteins are the main “drivers” of LPD, newer therapies that directly target EBV infection per se, such as EBV-directed T cells, are increasingly used to treat LPD, in addition to conventional chemotherapy and reduction of immunosuppression (Heslop et al., 2010; Prockop et al., 2020). Therapeutic antibodies that deplete CD20- or CD19-expressing B cells are also particularly useful for treating and/or preventing EBV-induced LPD, since they not only kill lymphoma cells but also eliminate the normal memory B cell reservoir for EBV latency (Kim et al., 2019).

Burkitt lymphomas (BLs)

EBV-positive BLs most frequently occur in sub-Saharan Africa, where *Plasmodium falciparum* malaria infection is very common (Magrath, 2012). Greater than 90% of BLs in this region (referred to as “endemic” BLs) are EBV-infected and usually present as jaw tumors in children (Magrath, 2012). In contrast, BLs in other parts of the world (“sporadic” BLs) are usually EBV-negative. Both EBV-positive and EBV-negative BLs are driven by over-expression of the cellular c-myc oncogene, usually due to chromosomal translocations that place it under the control of one of the immunoglobulin gene enhancers. C-myc translocation likely occurs as an “accident” during the germinal center (GC) reaction in lymph nodes due to increased expression of the activation-induced cytosine deaminase (AID) enzyme. AID, which induces the DNA breaks required for immunoglobulin class-switching (Muramatsu et al., 2000), is expressed specifically in germinal center (GC) B cells and causes c-myc translocations to immunoglobulin loci as an “off-target” effect (Ramiro et al., 2004). *P. falciparum* infection has also been shown to contribute to the development of EBV-positive BLs by inducing polyclonal B-cell activation (Torgbor et al., 2014), enhancing AID expression in GC B cells (Simone et al., 2011) and greatly increasing the number of EBV-infected B cells (Moormann et al., 2007; Njie et al., 2009; Simone et al., 2011). P.

falciparum infection in children decreases the ability of T cells to control EBV infection (Moormann et al., 2007; Njie et al., 2009).

EBV infection is thought to promote BLs by suppressing apoptosis in cells over-expressing c-myc (Kennedy et al., 2003). Inhibition of apoptosis in human EBV-positive BLs is at least partially mediated by the virally-encoded BART microRNAs, which decrease expression of apoptosis-inducing proteins such as caspase 3 (Vereide et al., 2014; Vereide and Sugden, 2011). Finally, EBV may also play a more direct role in promoting BLs by increasing expression of the AID protein (Kalchschmidt et al., 2016).

Hodgkin Lymphomas

EBV is present in 30 to 40% of classical Hodgkin lymphomas (HLs)(Weiss et al., 1989; Wu et al., 1990). HLs are composed of malignant multinucleated Reid-Sternberg (HRS) cells surrounded by non-malignant inflammatory cells (particularly CD4 T cells) that support the growth of the HRS cells (Mathas et al., 2016). Individuals who develop IM have an approximately four-fold increased risk of subsequently developing EBV-positive (but not EBV-negative) HL (Alexander et al., 2003; Hjalgrim et al., 2003). EBV-positive HLs have “type II” viral latency and express the LMP1 and LMP2A viral oncoproteins in the malignant HRS cells (Deacon et al., 1993). HRS cells, which are derived from post-germinal center B cells downregulate B cell specific markers and commonly contain cellular mutations that activate the NF κ B and JAK/STAT signaling pathways (Tiacci et al., 2018; Weniger and Küppers, 2021). Cellular mutations that activate the NF- κ B pathway are much less common in EBV-positive versus EBV-negative HLs (Weniger and Küppers, 2021), presumably because both LMP1 and LMP2A can induce NF-KB signaling. Furthermore, approximately 25% of EBV-positive HLs contain crippling mutations in the B cell receptor that would normally induce B cell death (Bräuninger et al., 2006), and LMP2A rescues survival of BCR-deficient B cells (Mancao and Hammerschmidt, 2007). Therefore, LMP2A functions as a surrogate BCR receptor in HRS cells. A naturally occurring EBV mutant (with a deleted EBNA2 gene that prevents type III latency) induces HL-like lymphomas with type II latency in a humanized mouse model (Li et al., 2020).

Diffuse large B cell lymphomas (DLBCLs)

Approximately 9% of DLBCLs, the most common type of non-Hodgkin lymphoma, are EBV positive world-wide (Malpica et al., 2022). EBV+ DLBCLs are now referred to as EBV+ DLBCL NOS (not otherwise specified). Most EBV+ positive DLBCLs support type II viral latency, although some have type III latency (particularly in the elderly and immunosuppressed) and rarely DLBCLs have type I latency (Bourbon et al., 2021) EBV infection is found in both the germinal center (GC)-type and “activated B cell” (ABC) type DLBCLs but is more common in ABC DLBCLs. EBV-positive DLBCLs more commonly show phenotypic activation of the JAK/STAT and NF- κ B pathways compared to EBV-negative DLBCLs consistent with the ability of LMP1 and LMP2A to activate these pathways (Ok et al., 2014). In addition, EBV-positive DLBCLs are less likely than EBV-negative DLBCLs to have mutations in the MYD88 and CD79B genes (Kataoka et al., 2019) suggesting that LMP2A and/or LMP1 expression compensates for these mutations.

However, much larger studies comparing cellular gene mutations in EBV-positive versus EBV-negative DLBCLs need to be performed.

NK and T cell lymphoproliferative diseases

EBV infection can induce several different types of malignant and non-malignant diseases in T cells and NK cells, particularly in Asia and Central/South America. Malignancies associated with EBV infection of NK and T cells include extranodal NK/T cell lymphoma, systemic EBV-associated T-cell lymphoma, and aggressive NK-cell leukemia (Cohen et al., 2020). Persistent EBV infection of NK cells and/or T cells can also cause chronic active EBV disease (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) (Cohen, 2000; Kimura et al., 2003). These diseases have over-lapping epidemiologic, clinical, and genetic features, and are characterized by EBV infection of NK and/or T cells (usually with type II EBV latency) (Cohen, 2000; Kimura et al., 2003). EBV-induced HLH results from release of excessive levels of macrophage-activating cytokines (such as IFN γ and TNF α) from EBV-infected NK/T cells. Patients with EBV-HLH are at high risk for subsequently developing CAEBV and/or EBV-induced NK or T cell lymphomas, CAEBV is now considered to be a NK cell/T cell lymphoproliferative disease (Cohen, 2000; Kimura et al., 2003) and patients have an increased risk of developing NK or T cell lymphomas (NKTCLs) (Okuno et al., 2019). Thus, EBV-infected NK cells and T cells in CAEBV patients may be derived from a common EBV-infected progenitor lymphoid cell which can differentiate into either cell type. Interestingly, clonal deletions of the EBV genome that remove the BART microRNAs are found in 35% of CAEBV lymphocytes, and up to 43% of NKTCLs, but not in the EBV genomes of patients with IM (Okuno et al., 2019; Wongwiwat et al., 2022). Since BART microRNAs decrease expression of the lytic EBV proteins, BZLF1 and BRLF1 (Jung et al., 2014), loss of BARTs in EBV-infected NK/T cell diseases may be selected for in certain tumors/diseases to enhance expression of early lytic proteins. Currently, the most effective therapy for severe CAEBV is early HSC transplant (Dávila Saldaña et al., 2022).

Nasopharyngeal Carcinoma

The association of EBV with NPC was initially suggested by the unusually elevated antibody titers to specific viral antigens. The IgA titers that are indicative of NPC suggested that viral antigens were made within the tumor and induced a mucosal antibody response (Henle and Henle, 1976). EBV lytic antigens induce IgA antibodies that serve as specific markers for the detection, development, and re-occurrence of NPC. NPC develops with a high incidence of 20–50 cases per 100,000 in the endemic regions of Southern China and with elevated incidence in Mediterranean, Middle Eastern, and Inuit populations (Raab-Traub, 2015). Three subtypes of NPC are distinguished by their degree of differentiation and the virus is found in all three subtypes.

Importantly, EBV is present in the malignant epithelial cells in NPC and not in the lymphoid infiltrate. Analysis of EBV expression in NPC identified Type II latency including transcription of LMP1 and LMP2 (Raab-Traub, 2015). Clonal viral DNA present in NPC indicates that the cells arose from a clonal origin i.e. a single EBV-infected cell (Raab-Traub and Flynn, 1986). A major contributing factor in the development of NPC is from

environmental exposures (including nutritional mutagens) that introduce preconditioning genetic changes in epithelial cells for NPC development and facilitate EBV latent infection. The essential contribution of EBV is evidenced by the universal retention of the EBV episome in NPC cells as well as expression of viral genes in every cell.

Multiple cellular tumor suppressor genes and oncogenes that are frequently mutated in carcinomas are not changed in NPC likely reflecting the properties of EBV genes that regulate the expression or function of these proteins, eliminating the selection for genetic activation or inactivation. The p53 tumor suppressor is not mutated in NPC due to LMP1's inhibition of p53-induced apoptosis (Fries et al., 1996). Similarly, the induction of expression of the epidermal growth factor receptor (EGFR) is induced to high levels by LMP1. The activation of Akt by LMP2 eliminates the need for genetic inactivation of PTEN or mutational activation of β -catenin, which is detected at high levels in the nucleus in NPC (Morrison et al., 2004). Intriguingly in a subset of tumors, mutations have been identified within the NF- κ B pathway including deletion of I κ B-alpha, and mutations in TRAF3 and A20 which can negatively regulate activation (Chung et al., 2013b). These changes would lead to constitutive activation of this pathway in the absence of LMP1, confirming its importance to NPC pathogenesis. Subsequent work has determined that LMP1 expression and NF- κ B activating mutations are mutually exclusive (Bruce et al., 2021). The strong endemic incidence of NPC has promoted many studies of NPC variants and variants in EBNA1, EBER2, the Z promoter and the BALF2 gene have been identified.

Additionally, abundant expression of the BART miRNAs in NPC suggests that the miRNAs likely impact development and progression. In the C15 NPC xenograft, 57% of the total miRNAs were BART miRNAs, and in the C666 NPC xenograft, the BART miRNAs represented 40% of all miRNAs (Marquitz et al., 2014). The highly abundant BART miRNAs found in NPC tumors may reflect a selection for BART miRNA expression. Genes involved in apoptosis e.g. Bim, PUMA and TOMM22 have been shown to be targets of various BART miRNAs in addition to genes involved in inhibition of T-cell responses to infected cells (Murer et al., 2019). It is likely that the specific targets may differ between cell lines and individual tumors, however, through the targeting of immune recognition, induction of cell invasion and metastasis, and promotion of tumorigenesis, the BART miRNAs are important factors in the development of NPC.

Gastric Carcinoma

Gastric carcinoma (GC) is a major cancer with significant worldwide incidence with over one million cases per year and 800,000 deaths. Approximately 10% of all GC is linked to EBV and unlike NPC, EBV associated GC does not have endemic patterns of incidence. However, EBV associated GC is distinguished from other GC by a considerable lymphoid infiltrate (Strong et al., 2013). GC is also unique in that the tumor genome is heavily methylated and the EBV positive GC is distinguished by extremely high methylation termed CpG island Methylator Phenotype (CIMP). It has been shown that chromatin structure and CpG methylation are major contributors to the maintenance of the EBV latency state and in GC, EBV expression is restricted to type I or II latency. EBV can induce hypermethylation to modify viral and cellular expression in epithelial cells (Stanland and Luftig, 2020).

Sequence analyses have shown a lack of mutation in p53 and frequent mutations in PI3K as well as amplification of the PDL1/PDL2 locus. Since EBV-positive GC has a better prognosis compared to EBV-negative GC and are remarkably responsive to immune checkpoint inhibitors (Kim et al., 2018), screening all GCs for the presence of EBV is probably warranted.

Autoimmune diseases associated with EBV

EBV infection has been linked to several autoimmune related disorders including systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, and multiple sclerosis.

There is a strong correlation between EBV infection and systemic lupus erythematosus. Individuals with systemic lupus erythematosus (SLE) display increased EBV antibody titers and viral DNA. Anti-EBNA1 antibodies appear to cross-react with SLE autoantigens, including Ro, Sm B/B', and Sm D1 (Poole et al., 2006). Moreover, a study that examined transcription factor binding to the human genome revealed that the EBV EBNA2 protein binds to regulatory regions associated with SLE as well as other autoimmune disorders including multiple sclerosis, rheumatoid arthritis etc. (Harley et al., 2018).

Similar to SLE patients, rheumatoid arthritis patients also display increased EBV viral DNA in their blood. These patients have a two-fold increased risk of developing lymphoma (Callan, 2004) and EBV infection does not appear to be well controlled by their T cells. The numbers of EBV-infected B lymphocytes are also elevated (Balandraud and Roudier, 2018).

In multiple sclerosis (MS), the myelin sheath of the central nervous system is under attack by autoreactive lymphocytes. Multiple epidemiological studies have associated EBV infection with MS and EBV-induced mononucleosis has been linked to an elevated risk of MS (Levin et al., 2010). A study of over 10 million military personnel in the U.S. revealed an increased rate of EBV infection in MS patients compared to controls and EBV-infected individuals were 32 times more likely to develop MS (Bjornevik et al., 2022). Furthermore, Neurofilament light chain (NfL) is a marker for neuroaxonal degeneration and NfL levels were significantly elevated in the sera of EBV-infected individuals with MS (Bjornevik et al., 2022). Another study reported the presence of cross-reactive cerebrospinal fluid (CSF) antibodies against EBV EBNA1 and human glial cell adhesion molecule (GlialCAM) in the central nervous system due to shared homology between the viral and human proteins (Lanz et al., 2022). Thus, molecular mimicry of viral and CNS myelin antigens is responsible for the pathological disease process and both anti-EBNA1 and anti-GlialCAM antibodies were found in MS patients. T cell responses against EBV proteins also cross-react with CNS proteins; for example, EBNA1-specific T cells in patients with MS cross-react with myelin antigens (Lunemann et al., 2008). Furthermore, in an autoimmune encephalomyelitis (EAE) mouse model of MS, injection of EBNA1 protein worsened disease (Lanz et al., 2022). Moreover, it has been reported that a significant number of brain-infiltrating B cells and plasma cells displayed EBV infection in 21 out of 22 post-mortem MS brain specimens (Serafini et al., 2007). Postmortem brains of MS patients also displayed CD8 cytotoxic T lymphocytes that recognize EBV latent and lytic proteins and interact with EBV-infected B cells (Serafini et al., 2019).

CONCLUSIONS

The 58 years since the discovery of EBV as a human tumor virus have been a remarkable foray into disease pathogenesis, growth control, molecular interactions, viral and cellular regulation, and environmental and genetic cofactors. These studies have shown that EBV can effectively thwart innate and adaptive immune responses, inhibit apoptotic and differentiation pathways and enhance cell proliferation and angiogenesis (Figure 3). The outcome of infection in any specific cell can be quite variable with either replication or multiple states of non-replicative or “latent” infections. Importantly, this cycling of latency and reactivation is ongoing in all infected individuals increasing the likelihood that an unfortunate combination will occur; perhaps EBV infection of a germinal center cell in the process of class switching resulting in Burkitt lymphoma or infection of a mutant B cell normally destined to die due to a non-functional BCR that is instead rescued by EBV thereby resulting in Hodgkin lymphoma. In southern China, the prevalence of a highly replicative variant increases the likelihood of infection of a nasopharyngeal epithelial cell with a set of mutations that activate cellular pathways that complement EBV transforming proteins and allow the virus to establish viral latency. Alternatively, EBV may enter a cell and induce extensive cellular genome methylation such as found in gastric cancer and NPC and can successfully establish infection and modulate cell proliferation through its abundant ncRNAs.

Additionally, both the initial immune response and the ongoing immune control can result in distinct outcomes and contribute to the development of infectious mononucleosis or in devastating long-term effects of autoimmune diseases including multiple sclerosis. The complexity of the disease process in these many different outcomes of infection seems daunting given that this is a virus that infects most people in the world and establishes a lifelong infection. However, this complexity also offers many opportunities for therapeutic intervention. In addition to the highly successful EBV-specific cytotoxic T-cell therapy, new drugs for specific targeting of critical pathways including NF κ B, PI3K, EGFR, and inhibitors of Src, Syk or Btk kinases may be beneficial.

This panoply of devastating outcomes to EBV infection underscores the considerable need for an EBV vaccine, preferably one so effective that infection is completely blocked. An attenuated vaccine that still establishes a persistent infection such as the initial zoster vaccine would have the same possibilities for causing disease and may in fact be worse. Fortunately, there have been very encouraging results with several EBV vaccine prototypes. A phase I clinical trial based on a single glycoprotein, gp350, has just begun at NIH ([NCT04645147](https://clinicaltrials.gov/ct2/show/study/NCT04645147)). Perhaps likely to be more effective is a self-assembling nanoparticle comprised of either 3 or 4 EBV glycoproteins gH/gL/gp42/gp350 used for entry into B cells and epithelial cells (Wei et al., 2022). This has induced significant humoral response and blocked infection in humanized mouse models (Wei et al., 2022). The eventual development of a sterilizing vaccine will finally reveal the essential role of EBV in the multiple cancers that contain the virus and express its gene products in every cell. Importantly, it will also identify pathologies linked to continual immune anti-EBV hyperactivity such as MS and potentially other diseases where traces of EBV have been shown. Nevertheless, a vaccine that attenuates lytic EBV infection without preventing infection may still have significant ability to prevent

IM and possibly also reduce the likelihood of EBV-induced cancers and auto-immune diseases.

Acknowledgements:

We sincerely apologize for omitting many important references in the field due to space restrictions. BD is supported by NIH grants DE028211, CA163217, CA228172, and CA239583; SK is supported by NIH grants CA232616, AI147060, CA229673, and CA022443; NRT is supported by NIH grant CA019014. The authors dedicate this review article to Dr. Joseph S. Pagano in recognition of his scientific contributions, insightful guidance, and unwavering support.

REFERENCES

- Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, and Hornung V (2009). RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. *Nature Immunology* 10, 1065–1072. [PubMed: 19609254]
- Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, et al. (2016). Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America* 113, E6467–E6475. [PubMed: 27698133]
- Alexander FE, Lawrence DJ, Freeland J, Krajewski AS, Angus B, Taylor GM, and Jarrett RF (2003). An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. *International journal of cancer Journal international du cancer* 107, 298–302. [PubMed: 12949811]
- Anderson LJ, and Longnecker R (2009). Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. *Blood* 113, 108–116. [PubMed: 18815281]
- Aubry V, Mure F, Mariamé B, Deschamps T, Wyrwicz LS, Manet E, and Gruffat H (2014). Epstein-Barr virus late gene transcription depends on the assembly of a virus-specific preinitiation complex. *J Virol* 88, 12825–12838. [PubMed: 25165108]
- Balandraud N, and Roudier J (2018). Epstein-Barr virus and rheumatoid arthritis. *Joint Bone Spine* 85, 165–170. [PubMed: 28499895]
- Balfour HH Jr., Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, and Hogquist KA (2013a). Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. *J Infect Dis* 207, 80–88. [PubMed: 23100562]
- Balfour HH Jr., Sifakis F, Sliman JA, Knight JA, Schmeling DO, and Thomas W (2013b). Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6–19 years in the United States and factors affecting its acquisition. *J Infect Dis* 208, 1286–1293. [PubMed: 23868878]
- Bentz GL, Bheda-Malge A, Wang L, Shackelford J, Damania B, and Pagano JS (2014). KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation. *Virology* 448, 293–302. [PubMed: 24314660]
- Bentz GL, Whitehurst CB, and Pagano JS (2011). Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9. *J Virol* 85, 10144–10153. [PubMed: 21795333]
- Bhende PM, Seaman WT, Delecluse HJ, and Kenney SC (2004). The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. *Nat Genet* 36, 1099–1104. [PubMed: 15361873]
- Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, et al. (2022). Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science* 375, 296–301. [PubMed: 35025605]
- Borza CM, and Hutt-Fletcher LM (2002). Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. *Nat Med* 8, 594–599. [PubMed: 12042810]
- Bourbon E, Maucort-Boulch D, Fontaine J, Mauduit C, Sesques P, Safar V, Ferrant E, Golfier C, Ghergus D, Karlin L, et al. (2021). Clinicopathological features and survival in EBV-positive

diffuse large B-cell lymphoma not otherwise specified. *Blood Adv* 5, 3227–3239. [PubMed: 34427583]

- Bräuninger A, Schmitz R, Bechtel D, Renné C, Hansmann ML, and Küppers R (2006). Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. *International journal of cancer Journal international du cancer* 118, 1853–1861. [PubMed: 16385563]
- Bristol JA, Brand J, Ohashi M, Eichelberg MR, Casco A, Nelson SE, Hayes M, Romero-Masters JC, Baiu DC, Gumperz JE, et al. (2022). Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. *PLoS Pathog* 18, e1010453. [PubMed: 35472072]
- Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M, Hayes M, Romero-Masters JC, Barlow EA, Farrell PJ, Rochford R, et al. (2018). A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. *PLoS Pathog* 14, e1007179. [PubMed: 30052684]
- Bruce JP, To KF, Lui VWY, Chung GTY, Chan YY, Tsang CM, Yip KY, Ma BBY, Woo JKS, Hui EP, et al. (2021). Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-kappaB activation and immune escape. *Nat Commun* 12, 4193. [PubMed: 34234122]
- Bu W, Joyce MG, Nguyen H, Banh DV, Aguilar F, Tariq Z, Yap ML, Tsujimura Y, Gillespie RA, Tsybovsky Y, et al. (2019). Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. *Immunity* 50, 1305–1316 e1306. [PubMed: 30979688]
- Burton EM, Goldbach-Mansky R, and Bhaduri-McIntosh S (2020). A promiscuous inflammasome sparks replication of a common tumor virus. *Proceedings of the National Academy of Sciences of the United States of America* 117, 1722–1730. [PubMed: 31919284]
- Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, and Cullen BR (2006). Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. *PLoS Pathog* 2, e23. [PubMed: 16557291]
- Callan MF (2004). Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. *Curr Opin Rheumatol* 16, 399–405. [PubMed: 15201603]
- Chen J, and Longnecker R (2019). Epithelial cell infection by Epstein-Barr virus. *FEMS Microbiol Rev* 43, 674–683. [PubMed: 31584659]
- Chen J, Sathiyamoorthy K, Zhang X, Schaller S, Perez White BE, Jardetzky TS, and Longnecker R (2018). Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. *Nat Microbiol* 3, 172–180. [PubMed: 29292384]
- Cheng AZ, Yockteng-Melgar J, Jarvis MC, Malik-Soni N, Borozan I, Carpenter MA, McCann JL, Ebrahimi D, Shaban NM, Marcon E, et al. (2019). Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity. *Nat Microbiol* 4, 78–88. [PubMed: 30420783]
- Chesnokova LS, Ahuja MK, and Hutt-Fletcher LM (2014). Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB. *J Virol* 88, 12193–12201. [PubMed: 25142593]
- Chiang JJ, Sparrer KMJ, van Gent M, Lassig C, Huang T, Osterrieder N, Hopfner KP, and Gack MU (2018). Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated immunity. *Nat Immunol* 19, 53–62. [PubMed: 29180807]
- Chijioko O, Landtwing V, and Munz C (2016). NK Cell Influence on the Outcome of Primary Epstein-Barr Virus Infection. *Front Immunol* 7, 323. [PubMed: 27621731]
- Chiu Y-H, Macmillan JB, and Chen ZJ (2009). RNA Polymerase III Detects Cytosolic DNA and Induces Type I Interferons through the RIG-I Pathway. *Cell* 138, 576–591. [PubMed: 19631370]
- Chiu YF, Sugden AU, and Sugden B (2013). Epstein-Barr viral productive amplification reprograms nuclear architecture, DNA replication, and histone deposition. *Cell Host Microbe* 14, 607–618. [PubMed: 24331459]
- Chung BK, Tsai K, Allan LL, Zheng DJ, Nie JC, Biggs CM, Hasan MR, Kozak FK, van den Elzen P, Priatel JJ, et al. (2013a). Innate immune control of EBV-infected B cells by invariant natural killer T cells. *Blood* 122, 2600–2608. [PubMed: 23974196]
- Chung GT, Lou WP, Chow C, To KF, Choy KW, Leung AW, Tong CY, Yuen JW, Ko CW, Yip TT, et al. (2013b). Constitutive activation of distinct NF-kappaB signals in EBV-associated nasopharyngeal carcinoma. *J Pathol* 231, 311–322. [PubMed: 23868181]

- Cohen JI (2000). Epstein-Barr virus infection. *N Engl J Med* 343, 481–492. [PubMed: 10944566]
- Cohen JI, Iwatsuki K, Ko YH, Kimura H, Manoli I, Ohshima K, Pittaluga S, Quintanilla-Martinez L, and Jaffe ES (2020). Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. *Leuk Lymphoma* 61, 808–819. [PubMed: 31833428]
- Countryman J, and Miller G (1985). Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. *Proceedings of the National Academy of Sciences of the United States of America* 82, 4085–4089. [PubMed: 2987963]
- Dávila Saldaña BJ, John T, Bonifant C, Buchbinder D, Chandra S, Chandrakasan S, Chang W, Chen L, Elfassy HL, Geerlinks AV, et al. (2022). High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. *Blood Adv* 6, 452–459. [PubMed: 34670275]
- Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, and Young LS (1993). Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. *J Exp Med* 177, 339–349. [PubMed: 8381153]
- Deng Z, Chen CJ, Chamberlin M, Lu F, Blobel GA, Speicher D, Cirillo LA, Zaret KS, and Lieberman PM (2003). The CBP bromodomain and nucleosome targeting are required for Zta-directed nucleosome acetylation and transcription activation. *Mol Cell Biol* 23, 2633–2644. [PubMed: 12665567]
- Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D, Nadal D, Norman PJ, Munz C, and Parham P (2017). Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and gammadelta T cells. *J Exp Med* 214, 1827–1841. [PubMed: 28468758]
- Djavadian R, Chiu YF, and Johannsen E (2016). An Epstein-Barr Virus-Encoded Protein Complex Requires an Origin of Lytic Replication In Cis to Mediate Late Gene Transcription. *PLoS Pathog* 12, e1005718. [PubMed: 27348612]
- Duan Y, Li Z, Cheng S, Chen Y, Zhang L, He J, Liao Q, Yang L, Gong Z, and Sun L-Q (2015). Nasopharyngeal carcinoma progression is mediated by EBV-triggered inflammation via the RIG-I pathway. *Cancer Letters* 361, 67–74. [PubMed: 25721089]
- Edwards RH, Marquitz AR, and Raab-Traub N (2015). Changes in expression induced by Epstein-Barr Virus LMP1-CTAR1: potential role of bcl3. *mBio* 6.
- Ernst R, Claessen JH, Mueller B, Sanyal S, Spooner E, van der Veen AG, Kirak O, Schlieker CD, Weihofen WA, and Ploegh HL (2011). Enzymatic blockade of the ubiquitin-proteasome pathway. *PLoS Biol* 8, e1000605. [PubMed: 21468303]
- Farrell PJ, and White RE (2021). Do Epstein-Barr Virus Mutations and Natural Genome Sequence Variations Contribute to Disease? *Biomolecules* 12.
- Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J, Manet E, Tommasino M, Sylla BS, and Hasan UA (2010). EBV latent membrane protein 1 is a negative regulator of TLR9. *Journal of immunology (Baltimore, Md : 1950)* 185, 6439–6447.
- Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, and Delecluse HJ (2000). The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. *EMBO J* 19, 3080–3089. [PubMed: 10856251]
- Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, and Fearon DT (1984). Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. *Proceedings of the National Academy of Sciences of the United States of America* 81, 4510–4514. [PubMed: 6087328]
- Fixman ED, Hayward GS, and Hayward SD (1992). trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. *J Virol* 66, 5030–5039. [PubMed: 1321285]
- Flemington EK, Borrás AM, Lytle JP, and Speck SH (1992). Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain. *J Virol* 66, 922–929. [PubMed: 1309920]
- Fotheringham JA, and Raab-Traub N (2015). Epstein-Barr virus latent membrane protein 2 induces autophagy to promote abnormal acinus formation. *J Virol* 89, 6940–6944. [PubMed: 25878108]
- Fries KL, Miller WE, and Raab-Traub N (1996). Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. *J Virol* 70, 8653–8659. [PubMed: 8970991]

- Gaudreault E, Fiola SP, Olivier M, and Gosselin J (2007). Epstein-Barr Virus Induces MCP-1 Secretion by Human Monocytes via TLR2. *Journal of Virology* 81, 8016–8024. [PubMed: 17522215]
- Gewurz BE, Towfic F, Mar JC, Shinnars NP, Takasaki K, Zhao B, Cahir-McFarland ED, Quackenbush J, Xavier RJ, and Kieff E (2012). Genome-wide siRNA screen for mediators of NF-kappaB activation. *Proceedings of the National Academy of Sciences of the United States of America* 109, 2467–2472. [PubMed: 22308454]
- Gewurz BL, RM.; Cohen JI (2021). Epstein-Barr Virus (Chapter 11). *Fields Virology*, 324–388.
- Gilligan KJ, Rajadurai P, Lin JC, Busson P, Abdel-Hamid M, Prasad U, Tursz T, and Raab-Traub N (1991). Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. *J Virol* 65, 6252–6259. [PubMed: 1656092]
- Gregory SM, West JA, Dillon PJ, Hilscher C, Dittmer DP, and Damania B (2009). Toll-like receptor signaling controls reactivation of KSHV from latency. *Proceedings of the National Academy of Sciences of the United States of America* 106, 11725–11730. [PubMed: 19564611]
- Griffin BD, Gram AM, Mulder A, Van Leeuwen D, Claas FH, Wang F, Rensing ME, and Wiertz E (2013). EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail. *Journal of immunology (Baltimore, Md : 1950)* 190, 1672–1684.
- Guo R, Jiang C, Zhang Y, Govande A, Trudeau SJ, Chen F, Fry CJ, Puri R, Wolinsky E, Schineller M, et al. (2020a). MYC Controls the Epstein-Barr Virus Lytic Switch. *Mol Cell* 78, 653–669.e658. [PubMed: 32315601]
- Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, Doench JG, O'Reilly RJ, Cesarman E, Giulino-Roth L, et al. (2020b). DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. *Nat Microbiol*.
- Gupta S, Ylä-Anttila P, Sandalova T, Sun R, Achour A, and Masucci MG (2019). 14-3-3 scaffold proteins mediate the inactivation of trim25 and inhibition of the type I interferon response by herpesvirus deconjugases. *PLoS Pathog* 15, e1008146. [PubMed: 31710640]
- Hammerschmidt W, and Sugden B (1988). Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. *Cell* 55, 427–433. [PubMed: 2846181]
- Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, Hammerschmidt W, O'Neill LA, and Masters SL (2012). Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1 β production. *Journal of immunology (Baltimore, Md : 1950)* 189, 3795–3799.
- Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, Magnusen AF, Lynch A, Chetal K, Yukawa M, et al. (2018). Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. *Nat Genet* 50, 699–707. [PubMed: 29662164]
- Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, and Mosialos G (1998). A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. *Journal of immunology (Baltimore, Md : 1950)* 160, 1116–1121.
- Henle G, and Henle W (1976). Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. *International journal of cancer Journal international du cancer* 17, 1–7. [PubMed: 175020]
- Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. *Blood* 115, 925–935. [PubMed: 19880495]
- Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS, Madsen M, Rosdahl N, Konradsen HB, Storm HH, et al. (2003). Characteristics of Hodgkin's lymphoma after infectious mononucleosis. *N Engl J Med* 349, 1324–1332. [PubMed: 14523140]
- Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, and Thorley-Lawson DA (2004). Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. *J Virol* 78, 5194–5204. [PubMed: 15113901]

- Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, and Kenney SC (2005a). Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. *J Virol* 79, 13993–14003. [PubMed: 16254335]
- Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, Polverini PJ, and Kenney SC (2005b). Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. *J Virol* 79, 13984–13992. [PubMed: 16254334]
- Hoshino Y, Katano H, Zou P, Hohman P, Marques A, Tyring SK, Follmann D, and Cohen JI (2009). Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. *J Virol* 83, 11857–11861. [PubMed: 19740997]
- Jochum S, Moosmann A, Lang S, Hammerschmidt W, and Zeidler R (2012). The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. *PLoS Pathog* 8, e1002704. [PubMed: 22615564]
- Jones RJ, Seaman WT, Feng WH, Barlow E, Dickerson S, Delecluse HJ, and Kenney SC (2007). Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. *International journal of cancer Journal international du cancer* 121, 1274–1281. [PubMed: 17520680]
- Jung YJ, Choi H, Kim H, and Lee SK (2014). MicroRNA miR-BART20–5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1. *J Virol* 88, 9027–9037. [PubMed: 24899173]
- Kalchschmidt JS, Bashford-Rogers R, Paschos K, Gillman AC, Styles CT, Kellam P, and Allday MJ (2016). Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. *J Exp Med* 213, 921–928. [PubMed: 27217538]
- Kalla M, Schmeink A, Bergbauer M, Pich D, and Hammerschmidt W (2010). AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. *Proceedings of the National Academy of Sciences of the United States of America* 107, 850–855. [PubMed: 20080764]
- Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, et al. (2019). Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. *Leukemia* 33, 1687–1699. [PubMed: 30683910]
- Kawai T, and Akira S (2008). Toll-like receptor and RIG-I-like receptor signaling. *Ann N Y Acad Sci* 1143, 1–20. [PubMed: 19076341]
- Kennedy G, Komano J, and Sugden B (2003). Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. *Proceedings of the National Academy of Sciences of the United States of America* 100, 14269–14274. [PubMed: 14603034]
- Kenney SC, and Mertz JE (2014). Regulation of the latent-lytic switch in Epstein-Barr virus. *Seminars in cancer biology* 26, 60–68. [PubMed: 24457012]
- Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, and Shin HY (2019). Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. *Transpl Infect Dis* 21, e13182. [PubMed: 31556214]
- Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al. (2018). Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* 24, 1449–1458. [PubMed: 30013197]
- Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, Imai S, Okano M, Morio T, Yokota S, et al. (2003). Prognostic factors for chronic active Epstein-Barr virus infection. *J Infect Dis* 187, 527–533. [PubMed: 12599068]
- Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, et al. (2009). Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. *Blood* 113, 1957–1966. [PubMed: 19005181]
- Kraus RJ, Yu X, Cordes BA, Sathiamoorthi S, Iempridee T, Nawandar DM, Ma S, Romero-Masters JC, McChesney KG, Lin Z, et al. (2017). Hypoxia-inducible factor-1 α plays roles in Epstein-Barr

- virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter. *PLoS Pathog* 13, e1006404. [PubMed: 28617871]
- Laichalk LL, and Thorley-Lawson DA (2005). Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. *J Virol* 79, 1296–1307. [PubMed: 15613356]
- Lange PT, White MC, and Damania B (2022). Activation and Evasion of Innate Immunity by Gammaherpesviruses. *J Mol Biol* 434, 167214. [PubMed: 34437888]
- Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, et al. (2022). Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. *Nature* 603, 321–327. [PubMed: 35073561]
- Levin LI, Munger KL, O'Reilly EJ, Falk KI, and Ascherio A (2010). Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. *Ann Neurol* 67, 824–830. [PubMed: 20517945]
- Li C, Romero-Masters JC, Huebner S, Ohashi M, Hayes M, Bristol JA, Nelson SE, Eichelberg MR, Van Sciver N, Ranheim EA, et al. (2020). EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. *PLoS Pathog* 16, e1008590. [PubMed: 32542010]
- Li X, Burton EM, and Bhaduri-McIntosh S (2017). Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells. *PLoS Pathog* 13, e1006249. [PubMed: 28249048]
- Li Z, Baccianti F, Delecluse S, Tsai MH, Shumilov A, Cheng X, Ma S, Hoffmann I, Poirey R, and Delecluse HJ (2021). The Epstein-Barr virus noncoding RNA EBER2 transactivates the UCHL1 deubiquitinase to accelerate cell growth. *Proceedings of the National Academy of Sciences of the United States of America* 118.
- Li Z, Tsai MH, Shumilov A, Baccianti F, Tsao SW, Poirey R, and Delecluse HJ (2019). Epstein-Barr virus ncRNA from a nasopharyngeal carcinoma induces an inflammatory response that promotes virus production. *Nat Microbiol* 4, 2475–2486. [PubMed: 31501540]
- Ling PD, Peng RS, Nakajima A, Yu JH, Tan J, Moses SM, Yang WH, Zhao B, Kieff E, Bloch KD, et al. (2005). Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. *EMBO J* 24, 3565–3575. [PubMed: 16177824]
- Liu X, Sadaoka T, Krogmann T, and Cohen JI (2020). Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Suppresses Type I Interferon Signaling To Promote EBV Reactivation. *J Virol* 94.
- Longnecker R, and Miller CL (1996). Regulation of Epstein-Barr virus latency by latent membrane protein 2. *Trends Microbiol* 4, 38–42. [PubMed: 8824794]
- Lu Y, Qin Z, Wang J, Zheng X, Lu J, Zhang X, Wei L, Peng Q, Zheng Y, Ou C, et al. (2017). Epstein-Barr Virus miR-BART6–3p Inhibits the RIG-I Pathway. *Journal of innate immunity* 9, 574–586. [PubMed: 28877527]
- Luftig M, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue J, Nakano H, Mak TW, Yeh WC, Li X, et al. (2003). Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. *Proceedings of the National Academy of Sciences of the United States of America* 100, 15595–15600. [PubMed: 14673102]
- Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, and Munz C (2008). EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. *J Exp Med* 205, 1763–1773. [PubMed: 18663124]
- Lunn RM, Jahnke GD, and Rabkin CS (2017). Tumour virus epidemiology. *Philos Trans R Soc Lond B Biol Sci* 372.
- Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, et al. (2011). A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. *J Virol* 85, 165–177. [PubMed: 20980506]
- Ma Z, and Damania B (2016). The cGAS-STING Defense Pathway and Its Counteraction by Viruses. *Cell Host Microbe* 19, 150–158. [PubMed: 26867174]
- Magrath I (2012). Epidemiology: clues to the pathogenesis of Burkitt lymphoma. *Br J Haematol* 156, 744–756. [PubMed: 22260300]

- Mahot S, Sergeant A, Drouet E, and Gruffat H (2003). A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. *J Gen Virol* 84, 965–974. [PubMed: 12655098]
- Mainou BA, Everly DN Jr., and Raab-Traub N (2007). Unique signaling properties of CTAR1 in LMP1-mediated transformation. *J Virol* 81, 9680–9692. [PubMed: 17626074]
- Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, and Castillo JJ (2022). EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. *Am J Hematol*.
- Mancao C, and Hammerschmidt W (2007). Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. *Blood* 110, 3715–3721. [PubMed: 17682125]
- Mannick JB, Cohen JI, Birkenbach M, Marchini A, and Kieff E (1991). The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. *J Virol* 65, 6826–6837. [PubMed: 1658376]
- Marquitz AR, Mathur A, Chugh PE, Dittmer DP, and Raab-Traub N (2014). Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. *J Virol* 88, 1389–1393. [PubMed: 24227849]
- Marquitz AR, Mathur A, Edwards RH, and Raab-Traub N (2015). Host Gene Expression Is Regulated by Two Types of Noncoding RNAs Transcribed from the Epstein-Barr Virus BamHI A Rightward Transcript Region. *J Virol* 89, 11256–11268. [PubMed: 26311882]
- Mathas S, Hartmann S, and Küppers R (2016). Hodgkin lymphoma: Pathology and biology. *Semin Hematol* 53, 139–147. [PubMed: 27496304]
- Meckes DG Jr., Shair KH, Marquitz AR, Kung CP, Edwards RH, and Raab-Traub N (2010). Human tumor virus utilizes exosomes for intercellular communication. *Proceedings of the National Academy of Sciences of the United States of America* 107, 20370–20375. [PubMed: 21059916]
- Messick TE, Smith GR, Soldan SS, McDonnell ME, Deakyne JS, Malecka KA, Tolvinski L, van den Heuvel APJ, Gu BW, Cassel JA, et al. (2019). Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth. *Sci Transl Med* 11.
- Miller N, and Hutt-Fletcher LM (1992). Epstein-Barr virus enters B cells and epithelial cells by different routes. *J Virol* 66, 3409–3414. [PubMed: 1316456]
- Miller WE, Cheshire JL, and Raab-Traub N (1998). Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. *Mol Cell Biol* 18, 2835–2844. [PubMed: 9566902]
- Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford R, and Kazura JW (2007). Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. *J Infect Dis* 195, 799–808. [PubMed: 17299709]
- Morrison JA, Gulley ML, Pathmanathan R, and Raab-Traub N (2004). Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. *Cancer Res* 64, 5251–5260. [PubMed: 15289331]
- Moss WN, Lee N, Pimienta G, and Steitz JA (2014). RNA families in Epstein-Barr virus. *RNA Biol* 11, 10–17. [PubMed: 24441309]
- Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, and Honjo T (2000). Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell* 102, 553–563. [PubMed: 11007474]
- Murer A, Ruhl J, Zbinden A, Capaul R, Hammerschmidt W, Chijioke O, and Munz C (2019). MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control In Vivo. *mBio* 10.
- Nawandar DM, Wang A, Makielski K, Lee D, Ma S, Barlow E, Reusch J, Jiang R, Wille CK, Greenspan D, et al. (2015). Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells. *PLoS Pathog* 11, e1005195. [PubMed: 26431332]
- Njie R, Bell AI, Jia H, Croom-Carter D, Chaganti S, Hislop AD, Whittle H, and Rickinson AB (2009). The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. *J Infect Dis* 199, 31–38. [PubMed: 19032105]

- Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, Tsokos GC, and Fingerth JD (2013). Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. *Cell Rep* 3, 371–385. [PubMed: 23416052]
- Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et al. (2014). Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. *Clin Cancer Res* 20, 2338–2349. [PubMed: 24583797]
- Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, et al. (2019). Defective Epstein-Barr virus in chronic active infection and haematological malignancy. *Nat Microbiol* 4, 404–413. [PubMed: 30664667]
- Pagano JS, Whitehurst CB, and Andrei G (2018). Antiviral Drugs for EBV. *Cancers (Basel)* 10.
- Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Wurdinger T, and Middeldorp JM (2010). Functional delivery of viral miRNAs via exosomes. *Proceedings of the National Academy of Sciences of the United States of America* 107, 6328–6333. [PubMed: 20304794]
- Pei Y, Banerjee S, Jha HC, Sun Z, and Robertson ES (2017). An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. *PLoS Pathog* 13, e1006500. [PubMed: 28738086]
- Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C, et al. (2004). Identification of virus-encoded microRNAs. *Science* 304, 734–736. [PubMed: 15118162]
- Pisano G, Roy A, Ahmed Ansari M, Kumar B, Chikoti L, and Chandran B (2017). Interferon- γ -inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency. *Virology Journal* 14.
- Poole BD, Scofield RH, Harley JB, and James JA (2006). Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. *Autoimmunity* 39, 63–70. [PubMed: 16455583]
- Price AM, Dai J, Bazot Q, Patel L, Nikitin PA, Djavadian R, Winter PS, Salinas CA, Barry AP, Wood KC, et al. (2017). Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. *eLife* 6.
- Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, et al. (2020). Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. *J Clin Invest* 130, 733–747. [PubMed: 31689242]
- Pudney VA, Leese AM, Rickinson AB, and Hislop AD (2005). CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. *J Exp Med* 201, 349–360. [PubMed: 15684323]
- Quinn LL, Williams LR, White C, Forrest C, Zuo J, and Rowe M (2016). The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II. *J Virol* 90, 356–367. [PubMed: 26468525]
- Raab-Traub N (2015). Nasopharyngeal Carcinoma: An Evolving Role for the Epstein-Barr Virus. *Curr Top Microbiol Immunol* 390, 339–363. [PubMed: 26424653]
- Raab-Traub N, and Dittmer DP (2017). Viral effects on the content and function of extracellular vesicles. *Nat Rev Microbiol* 15, 559–572. [PubMed: 28649136]
- Raab-Traub N, and Flynn K (1986). The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. *Cell* 47, 883–889. [PubMed: 3022942]
- Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M, Honjo T, Nussenzweig A, and Nussenzweig MC (2004). AID is required for c-myc/IgH chromosome translocations in vivo. *Cell* 118, 431–438. [PubMed: 15315756]
- Rickinson AB, Long HM, Palendira U, Munz C, and Hislop AD (2014). Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. *Trends Immunol* 35, 159–169. [PubMed: 24589417]
- Robertson ES, Lin J, and Kieff E (1996). The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). *J Virol* 70, 3068–3074. [PubMed: 8627785]

- Rooney CM, Rowe DT, Ragot T, and Farrell PJ (1989). The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. *J Virol* 63, 3109–3116. [PubMed: 2542618]
- Rostgaard K, Wohlfahrt J, and Hjalgrim H (2014). A genetic basis for infectious mononucleosis: evidence from a family study of hospitalized cases in Denmark. *Clin Infect Dis* 58, 1684–1689. [PubMed: 24696238]
- Saito S, Murata T, Kanda T, Isomura H, Narita Y, Sugimoto A, Kawashima D, and Tsurumi T (2013). Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF- κ B signaling during productive replication. *J Virol* 87, 4060–4070. [PubMed: 23365429]
- Samanta M, Iwakiri D, Kanda T, Imaizumi T, and Takada K (2006). EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. *EMBO J* 25, 4207–4214. [PubMed: 16946700]
- Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, et al. (2007). Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. *J Exp Med* 204, 2899–2912. [PubMed: 17984305]
- Serafini B, Rosicarelli B, Veroni C, Mazzola GA, and Aloisi F (2019). Epstein-Barr virus-specific CD8 T cells selectively infiltrate the multiple sclerosis brain and interact locally with virus infected cells: clue for a virus-driven immunopathological mechanism. *J Virol*.
- Shah KM, Stewart SE, Wei W, Woodman CB, O’Neil JD, Dawson CW, and Young LS (2009). The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. *Oncogene* 28, 3903–3914. [PubMed: 19718044]
- Simone O, Bejarano MT, Pierce SK, Antonaci S, Wahlgren M, Troye-Blomberg M, and Donati D (2011). TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1 α -driven human polyclonal B-cell activation. *Acta Trop* 119, 144–150. [PubMed: 21620790]
- Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, and Pagano JS (1984). Epstein-Barr virus replication in oropharyngeal epithelial cells. *N Engl J Med* 310, 1225–1230. [PubMed: 6323983]
- Smith C, Wakisaka N, Crough T, Peet J, Yoshizaki T, Beagley L, and Khanna R (2009). Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. *Blood* 113, 6148–6152. [PubMed: 19372256]
- Smith NA, Coleman CB, Gewurz BE, and Rochford R (2020). CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells. *J Virol* 94.
- Spriggs MK, Armitage RJ, Comeau MR, Strockbine L, Farrah T, Macduff B, Ulrich D, Alderson MR, Mullberg J, and Cohen JI (1996). The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. *J Virol* 70, 5557–5563. [PubMed: 8764069]
- Stanland LJ, and Luftig MA (2020). The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis. *Viruses* 12.
- Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, et al. (2013). Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. *PLoS Pathog* 9, e1003341. [PubMed: 23671415]
- Styles CT, Bazot Q, Parker GA, White RE, Paschos K, and Allday MJ (2017). EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency. *PLoS Biol* 15, e2001992. [PubMed: 28771465]
- Swaminathan S, Tomkinson B, and Kieff E (1991). Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. *Proceedings of the National Academy of Sciences of the United States of America* 88, 1546–1550. [PubMed: 1847527]
- Tanner J, Weis J, Fearon D, Whang Y, and Kieff E (1987). Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. *Cell* 50, 203–213. [PubMed: 3036369]
- Taylor GS, Long HM, Brooks JM, Rickinson AB, and Hislop AD (2015). The immunology of Epstein-Barr virus-induced disease. *Annu Rev Immunol* 33, 787–821. [PubMed: 25706097]

- Temple RM, Zhu J, Budgeon L, Christensen ND, Meyers C, and Sample CE (2014). Efficient replication of Epstein-Barr virus in stratified epithelium in vitro. *Proceedings of the National Academy of Sciences of the United States of America* 111, 16544–16549. [PubMed: 25313069]
- Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, Wang Y, Rosseto A, Venanzi A, Vlasevska S, et al. (2018). Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. *Blood* 131, 2454–2465. [PubMed: 29650799]
- Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca KA, and Thorley-Lawson DA (2014). A multifactorial role for *P. falciparum* malaria in endemic Burkitt's lymphoma pathogenesis. *PLoS Pathog* 10, e1004170. [PubMed: 24874410]
- Tsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse HJ, and Lieberman PM (2011). EBV tegument protein BNRF1 disrupts DAXX-ATRAX to activate viral early gene transcription. *PLoS Pathog* 7, e1002376. [PubMed: 22102817]
- Tzellos S, Correia PB, Karstegl CE, Cancian L, Cano-Flanagan J, McClellan MJ, West MJ, and Farrell PJ (2014). A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2. *J Virol* 88, 8743–8753. [PubMed: 24850736]
- Ungerleider NA, Tibbetts SA, Renne R, and Flemington EK (2019). Gammaherpesvirus RNAs Come Full Circle. *mBio* 10.
- van Gent M, Braem SG, de Jong A, Delagic N, Peeters JG, Boer IG, Moynagh PN, Kremmer E, Wiertz EJ, Ovaas H, et al. (2014). Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling. *PLoS Pathog* 10, e1003960. [PubMed: 24586164]
- van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, and Rensing ME (2011). EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. *Journal of immunology (Baltimore, Md : 1950)* 186, 1694–1702.
- Van Sciver N, Ohashi M, Nawandar DM, Pauly NP, Lee D, Makielski KR, Bristol JA, Tsao SW, Lambert PF, Johannsen EC, et al. (2021a). Np63 α promotes Epstein-Barr virus latency in undifferentiated epithelial cells. *PLoS Pathog* 17, e1010045. [PubMed: 34748616]
- Van Sciver N, Ohashi M, Pauly NP, Bristol JA, Nelson SE, Johannsen EC, and Kenney SC (2021b). Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells. *PLoS Pathog* 17, e1009783. [PubMed: 34339458]
- Vedham V, Verma M, and Mahabir S (2015). Early-life exposures to infectious agents and later cancer development. *Cancer Med* 4, 1908–1922. [PubMed: 26377256]
- Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A, Hammerschmidt W, and Sugden B (2014). Epstein-Barr virus maintains lymphomas via its miRNAs. *Oncogene* 33, 1258–1264. [PubMed: 23503461]
- Vereide DT, and Sugden B (2011). Lymphomas differ in their dependence on Epstein-Barr virus. *Blood* 117, 1977–1985. [PubMed: 21088132]
- Verma D, Church TM, and Swaminathan S (2020). Epstein-Barr virus co-opts TFIIF component XPB to specifically activate essential viral lytic promoters. *Proceedings of the National Academy of Sciences of the United States of America* 117, 13044–13055. [PubMed: 32434920]
- Vilmen G, Glon D, Siracusano G, Lussignol M, Shao Z, Hernandez E, Perdiz D, Quignon F, Mouna L, Potis C, et al. (2020). BHRF1, a BCL2 viral homolog, disturbs mitochondrial dynamics and stimulates mitophagy to dampen type I IFN induction. *Autophagy*, 1–20. [PubMed: 31516068]
- Wang HB, Zhang H, Zhang JP, Li Y, Zhao B, Feng GK, Du Y, Xiong D, Zhong Q, Liu WL, et al. (2015). Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. *Nat Commun* 6, 6240. [PubMed: 25670642]
- Wei CJ, Bu W, Nguyen LA, Batchelor JD, Kim J, Pittaluga S, Fuller JR, Nguyen H, Chou TH, Cohen JI, et al. (2022). A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. *Sci Transl Med* 14, eabf3685.
- Weiss LM, Movahed LA, Warnke RA, and Sklar J (1989). Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. *N Engl J Med* 320, 502–506. [PubMed: 2536894]

- Wen KW, Wang L, Menke JR, and Damania B (2021). Cancers associated with human gammaherpesviruses. *FEBS J*.
- Weniger MA, and Küppers R (2021). Molecular biology of Hodgkin lymphoma. *Leukemia* 35, 968–981. [PubMed: 33686198]
- Westhoff Smith D, Chakravorty A, Hayes M, Hammerschmidt W, and Sugden B (2021). The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells. *mBio* 12, e0224321. [PubMed: 34781735]
- Wille CK, Nawandar DM, Henning AN, Ma S, Oetting KM, Lee D, Lambert P, Johannsen EC, and Kenney SC (2015). 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch. *Proceedings of the National Academy of Sciences of the United States of America* 112, E7257–7265. [PubMed: 26663912]
- Wille CK, Nawandar DM, Panfil AR, Ko MM, Hagemeyer SR, and Kenney SC (2013). Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. *J Virol* 87, 935–950. [PubMed: 23135711]
- Wongwiwat W, Fournier B, Bassano I, Bayoumy A, Elgueta Karstegl C, Styles C, Bridges R, Lenoir C, BoutBoul D, Moshous D, et al. (2022). Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases. *J Virol*, e0039422. [PubMed: 35612313]
- Wu TC, Mann RB, Charache P, Hayward SD, Staal S, Lambe BC, and Ambinder RF (1990). Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. *International journal of cancer Journal international du cancer* 46, 801–804. [PubMed: 2172169]
- Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS, and Zhang Z (2017). TRIM29 promotes DNA virus infections by inhibiting innate immune response. *Nat Commun* 8, 945. [PubMed: 29038422]
- Yin Y, Manoury B, and Fahraeus R (2003). Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. *Science* 301, 1371–1374. [PubMed: 12958359]
- Yuling H, Ruijing X, Li L, Xiang J, Rui Z, Yujuan W, Lijun Z, Chunxian D, Xinti T, Wei X, et al. (2009). EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. *Cancer Res* 69, 7935–7944. [PubMed: 19808969]
- Zalani S, Holley-Guthrie E, and Kenney S (1996). Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. *Proceedings of the National Academy of Sciences of the United States of America* 93, 9194–9199. [PubMed: 8799177]
- Zhang H, Li Y, Wang HB, Zhang A, Chen ML, Fang ZX, Dong XD, Li SB, Du Y, Xiong D, et al. (2018). Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. *Nat Microbiol* 3, 1–8.




Figure 1. EBV Viral Entry.

Virion binding, attachment, and entry into the host cell is depicted. EBV can enter either through endocytosis or fusion with the plasma membrane. After the viral genome is injected into the nucleus, the virus can either enter latency or lytic replication depending on the cell type and environmental cues.




Figure 2. Molecular interactions and activation of cell signaling pathways by LMP1 and LMP2. (A) Latent membrane protein 1 (LMP1). LMP1 is located within lipid rafts and associates with proteins that facilitate exosome secretion (CD63) and function (galectin 9). The carboxy terminal activating domains, CTAR1 and CTAR2, and the interacting TRAF molecules are denoted. The resultant effects on cellular signaling complexes with activation of kinases and distinct forms of NFκB are indicated. (B) Latent membrane protein 2 (LMP2). Schematic representation of specific domains including the SH2 Src kinase binding domain, the ITAM Syk binding site, and PPY binding site for Nedd4 ubiquitin ligases. The critical pathways that are activated through these interactions and the inhibition of the B-cell receptor (BCR) are indicated.




Figure 3. EBV modulation of the infected cell.

EBV is a master regulator of the infected cell. EBV genes can inhibit apoptotic pathways (LMP1, EBNA1, BARTs) and enhance cell proliferation and transformation pathways (LMP1, LMP2A, EBNA1, EBNA2, EBERs), angiogenesis (LMP1, Z), as well as promote metastasis (LMP1, LMP2A). Several EBV genes also block growth suppressors (LMP1, EBNA3C, BARTs). Multiple EBV proteins (EBNA1, EBNA3C, LMP1, BALF3, BNRF1, BGLF5) have been demonstrated to induce genomic stability and dysregulate cell metabolic pathways (LMP1, LMP2A). EBV genes can also inhibit host innate and adaptive immune responses (EBNA1, EBERs, BARTs) and induce inflammatory cytokine and growth factor expression (LMP1, Z, R). Modulation of these pathways by EBV contribute to its oncogenic role in human malignancies. Additionally, EBV EBNA1 displays molecular mimicry with cellular proteins and contribute to EBV’s role in autoimmune diseases including multiple sclerosis.

TABLE 1:

EBV-associated cancers, latency type, and viral gene expression

EBV-ASSOCIATED DISEASE	LATENCY TYPE	EBV VIRAL GENE EXPRESSION
Healthy individuals	0	EBERs, BARTs
Burkitt lymphoma (BL)	I	EBERs, BARTs, EBNA1
Gastric carcinoma	I or II	EBERs, BARTs, EBNA1
Hodgkin lymphoma (HL)	II	EBERs, BARTs, EBNA1, LMP1, LMP2
NK/T cell lymphoma (NKTL)	II	EBERs, BARTs, EBNA1, LMP1, LMP2
Nasopharyngeal carcinoma (NPC)	II	EBERs, BARTs, EBNA1, LMP1, LMP2
Diffused large B cell lymphoma (DLBCL)	II or III	EBERs, BARTs, EBNA1, EBNA2, EBNA3A,B,C, EBNA-LP, BHRF1 miRNAs
HIV-associated lymphomas	III	EBERs, BARTs, EBNA1, LMP1, LMP2, EBNA2, EBNA-3A,B,C, EBNA-LP, BHRF1 miRNAs
Post-transplant lymphoproliferative disease (PTLD)	III	EBERs, BARTs, EBNA1, LMP1, LMP2, EBNA2, EBNA3A,B,C, EBNA-LP, BHRF1 miRNAs

Table 2:

EBV immune evasion proteins and ncRNAs

EBV gene	Function in immunity	Reference
BCRF1 (vIL-10)	Prevents B cells from being killed by NK cells. Impairs CD4+ T cell function	(Jochum et al., 2012)
BDLF3	Inhibits CD1 presentation of MHC class I and II molecules	(Quinn et al., 2016)
BGLF2	Binds Tyk2 and inhibits type I IFN	(Liu et al., 2020)
BGLF5	Degrades TLR9	(van Gent et al., 2011)
BHRF1	Degrades mitochondria and the MAVS protein, thereby reducing interferon signaling	(Vilmen et al., 2020)
BILF1	Induces degradation of HLA-A and HLA-B molecules	(Griffin et al., 2013)
BNLF2A	Prevents MHC class I presentation of viral antigens to CD8+ T cells.	(Jochum <i>et al.</i> , 2012)
BORF2	Inhibits APOBEC3B and innate immune responses	(Cheng et al., 2019)
BPLF1	Targets TRIF, MyD88, TRAF6 to inhibit TLR and NF- κ B activation.	(Saito et al., 2013; van Gent et al., 2014)
BZLF2 (gp42)	Prevents MHC class II antigen presentation to T cells	(Spriggs et al., 1996)
EBNA1	Controls its own protein synthesis preventing EBNA1 peptides from being presented to T cells. Downregulates the expression of NKG2D ligands to prevent NK cell-mediated killing of infected B cells.	(Yin et al., 2003) (Westhoff Smith et al., 2021).
LMP1	Suppresses TLR9 promoter	(Fathallah et al., 2010)
LMP2A and 2B	Target interferon receptors for degradation	(Shah et al., 2009)
miR-BART6-3p	Downregulates RIG-I and interferon response	(Lu et al., 2017)
miR-BART15	Inhibits NLRP3 expression	(Haneklaus et al., 2012)